Merck Exceeds Q1 Expectations with Strong Sales, Adjusted EPS Beat, and Upbeat Guidance
Summary
Merck reported a Q1 adjusted loss per share of $1.28, significantly better than the IBES estimate of a $1.51 loss, indicating a strong beat on profitability. The company also surpassed expectations on Q1 worldwide sales, reaching $16.29 billion against an estimated $15.82 billion, driven by robust performance from its blockbuster drug Keytruda, which posted $8 billion in sales versus an estimated $7.62 billion. While the reported GAAP and non-GAAP loss per share includes a $3.62 charge related to the Cidara acquisition, the underlying operational results were strong. Furthermore, Merck provided 2026 full-year adjusted EPS guidance of $5.04 to $5.16 and worldwide sales guidance of $65.8 billion to $67 billion, both slightly above analyst estimates. This comprehensive earnings report, featuring multiple beats and positive guidance, signals strong operational momentum for the pharmaceutical giant.
At the time of this announcement, MRK was trading at $115.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $274B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.